DE60331769D1 - Sten in der behandlung von u.a. sexueller dysfunktion - Google Patents

Sten in der behandlung von u.a. sexueller dysfunktion

Info

Publication number: DE60331769D1
Authority: DE; Germany
Prior art keywords: sten; treatment; sexual dysfunction; sexual; dysfunction
Prior art date: 2002-12-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE60331769T

Other languages

English (en)

Inventor

Charlotte Moira Allerton

Andrew Douglas Baxter

Andrew Simon Cook

David Hepworth

Stephen Kwok-Fung Wong

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pfizer Inc

Original Assignee

Pfizer Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-10

Filing date

2003-12-02

Publication date

2010-04-29

2002-12-10 Priority claimed from GB0228787A external-priority patent/GB0228787D0/en

2003-04-11 Priority claimed from GB0308460A external-priority patent/GB0308460D0/en

2003-06-12 Priority claimed from GB0313606A external-priority patent/GB0313606D0/en

2003-12-02 Application filed by Pfizer Inc filed Critical Pfizer Inc

2010-04-29 Application granted granted Critical

2010-04-29 Publication of DE60331769D1 publication Critical patent/DE60331769D1/de

2023-12-03 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

201000001880 Sexual dysfunction Diseases 0.000 title 1
231100000872 sexual dysfunction Toxicity 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Reproductive Health (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Gynecology & Obstetrics (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Child & Adolescent Psychology (AREA)
Hematology (AREA)
Psychology (AREA)
Addiction (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Pregnancy & Childbirth (AREA)
Diabetes (AREA)
Obesity (AREA)
Nutrition Science (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)

DE60331769T 2002-12-10 2003-12-02 Sten in der behandlung von u.a. sexueller dysfunktion Expired - Lifetime DE60331769D1 (de)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB0228787A GB0228787D0 (en)	2002-12-10	2002-12-10	Morpholine dopamine agonists
GB0308460A GB0308460D0 (en)	2003-04-11	2003-04-11	Morpholine dopamine agonists
GB0313606A GB0313606D0 (en)	2003-06-12	2003-06-12	Morpholine dopamine agonists
PCT/IB2003/005683 WO2004052372A1 (en)	2002-12-10	2003-12-02	Morpholine derivatives for use as dopamine agonists in the treatment of i.a. sexual dysfunction

Publications (1)

Publication Number	Publication Date
DE60331769D1 true DE60331769D1 (de)	2010-04-29

Family

ID=32512061

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE60331769T Expired - Lifetime DE60331769D1 (de)	2002-12-10	2003-12-02	Sten in der behandlung von u.a. sexueller dysfunktion

Country Status (37)

Country	Link
EP (1)	EP1572214B1 (de)
JP (3)	JP3889775B2 (de)
KR (1)	KR100796102B1 (de)
AP (1)	AP2005003325A0 (de)
AR (1)	AR042339A1 (de)
AT (1)	ATE460938T1 (de)
AU (1)	AU2003302878B2 (de)
CA (1)	CA2508262C (de)
CO (1)	CO5700781A2 (de)
CR (1)	CR7869A (de)
CY (1)	CY1110130T1 (de)
DE (1)	DE60331769D1 (de)
DK (1)	DK1572214T3 (de)
EA (1)	EA009589B1 (de)
EC (1)	ECSP055850A (de)
ES (1)	ES2339767T3 (de)
GE (1)	GEP20074272B (de)
HK (1)	HK1081850A1 (de)
HN (1)	HN2003000401A (de)
HR (1)	HRP20050523A2 (de)
IS (1)	IS7843A (de)
MA (1)	MA27605A1 (de)
MX (1)	MXPA05006151A (de)
MY (1)	MY144338A (de)
NL (1)	NL1024983C2 (de)
NO (1)	NO330143B1 (de)
NZ (1)	NZ540505A (de)
OA (1)	OA13014A (de)
PA (1)	PA8591601A1 (de)
PE (1)	PE20040906A1 (de)
PL (1)	PL377480A1 (de)
PT (1)	PT1572214E (de)
RS (1)	RS51442B (de)
SI (1)	SI1572214T1 (de)
TW (1)	TW200423944A (de)
UY (1)	UY28117A1 (de)
WO (1)	WO2004052372A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005116027A2 (en) *	2004-05-26	2005-12-08	Pfizer Limted	Indazole and indolone derivatives and their use as pharmaceuticals
JP4198183B2 (ja) *	2004-05-27	2008-12-17	ファイザー・インク	選択的ドーパミンｄ３アゴニストとしてのアミノピリジン誘導体
GB0502509D0 (en) *	2005-02-07	2005-03-16	Pfizer Ltd	Novel salt form of a dopamine agonist
TW200740779A (en)	2005-07-22	2007-11-01	Mitsubishi Pharma Corp	Intermediate compound for synthesizing pharmaceutical agent and production method thereof
GB0700786D0 (en) *	2007-01-15	2007-02-21	Pfizer Ltd	Morpholine dopamine agonists for the treatment of pain
JP2013526583A (ja)	2010-05-21	2013-06-24	リサーチ・トライアングル・インスティチュート	フェニルモルホリンおよびその類似体
JP5952267B2 (ja)	2010-05-21	2016-07-13	リサーチ・トライアングル・インスティチュート	薬物依存を処置するためのヒドロキシブプロピオン類似体（政府支援研究または開発）
KR20160097291A (ko)	2013-12-11	2016-08-17	에프. 호프만-라 로슈 아게	키랄 2-아릴 모폴린의 제조 방법
GB2543296A (en) *	2015-10-13	2017-04-19	Indivior Uk Ltd	Dopamine D3 receptor antagonists having a morpholine moiety
EP3725768A1 (de) *	2019-04-17	2020-10-21	Newron Pharmaceuticals S.p.A.	Verfahren zur herstellung von substituierten 2-[2-(phenyl)ethylamino]alkanamid-derivaten

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB851311A (en) *	1958-04-02	1960-10-12	Geigy Ag J R	Morpholine compounds and their production
GB9108629D0 (en) *	1991-04-23	1991-06-12	Wellcome Found	Heterocyclic pharmaceutical compounds,preparation and use
GB0130219D0 (en) *	2001-12-18	2002-02-06	Pfizer Ltd	Compounds for the treatment of sexual dysfunction

2003
- 2003-12-02 PT PT03812639T patent/PT1572214E/pt unknown
- 2003-12-02 SI SI200331801T patent/SI1572214T1/sl unknown
- 2003-12-02 WO PCT/IB2003/005683 patent/WO2004052372A1/en active Application Filing
- 2003-12-02 KR KR1020057010474A patent/KR100796102B1/ko not_active IP Right Cessation
- 2003-12-02 ES ES03812639T patent/ES2339767T3/es not_active Expired - Lifetime
- 2003-12-02 CA CA002508262A patent/CA2508262C/en not_active Expired - Fee Related
- 2003-12-02 DE DE60331769T patent/DE60331769D1/de not_active Expired - Lifetime
- 2003-12-02 AP AP2005003325A patent/AP2005003325A0/xx unknown
- 2003-12-02 RS YUP-2005/0445A patent/RS51442B/en unknown
- 2003-12-02 NZ NZ540505A patent/NZ540505A/en not_active IP Right Cessation
- 2003-12-02 OA OA1200500171A patent/OA13014A/en unknown
- 2003-12-02 GE GEAP20038838A patent/GEP20074272B/en unknown
- 2003-12-02 MX MXPA05006151A patent/MXPA05006151A/es active IP Right Grant
- 2003-12-02 JP JP2005502342A patent/JP3889775B2/ja not_active Expired - Fee Related
- 2003-12-02 EP EP03812639A patent/EP1572214B1/de not_active Expired - Lifetime
- 2003-12-02 AT AT03812639T patent/ATE460938T1/de active
- 2003-12-02 AU AU2003302878A patent/AU2003302878B2/en not_active Ceased
- 2003-12-02 DK DK03812639.7T patent/DK1572214T3/da active
- 2003-12-02 EA EA200500801A patent/EA009589B1/ru not_active IP Right Cessation
- 2003-12-02 PL PL377480A patent/PL377480A1/pl not_active Application Discontinuation
- 2003-12-05 PE PE2003001234A patent/PE20040906A1/es not_active Application Discontinuation
- 2003-12-08 MY MYPI20034690A patent/MY144338A/en unknown
- 2003-12-09 HN HN2003000401A patent/HN2003000401A/es unknown
- 2003-12-09 TW TW092134694A patent/TW200423944A/zh unknown
- 2003-12-09 AR ARP030104524A patent/AR042339A1/es unknown
- 2003-12-10 NL NL1024981A patent/NL1024983C2/nl not_active IP Right Cessation
- 2003-12-10 UY UY28117A patent/UY28117A1/es not_active Application Discontinuation
- 2003-12-10 PA PA20038591601A patent/PA8591601A1/es unknown
2005
- 2005-05-12 IS IS7843A patent/IS7843A/is unknown
- 2005-05-26 NO NO20052557A patent/NO330143B1/no not_active IP Right Cessation
- 2005-06-09 HR HR20050523A patent/HRP20050523A2/hr not_active Application Discontinuation
- 2005-06-10 CO CO05056566A patent/CO5700781A2/es not_active Application Discontinuation
- 2005-06-10 CR CR7869A patent/CR7869A/es unknown
- 2005-06-10 MA MA28324A patent/MA27605A1/fr unknown
- 2005-06-10 EC EC2005005850A patent/ECSP055850A/es unknown
2006
- 2006-02-17 HK HK06102107.0A patent/HK1081850A1/xx not_active IP Right Cessation
- 2006-06-06 JP JP2006157609A patent/JP3920908B2/ja not_active Expired - Fee Related
- 2006-12-27 JP JP2006352505A patent/JP4624341B2/ja not_active Expired - Fee Related
2010
- 2010-04-26 CY CY20101100367T patent/CY1110130T1/el unknown

Also Published As

Publication number	Publication date
EP1572214A1 (de)	2005-09-14
JP2006511599A (ja)	2006-04-06
HK1081850A1 (en)	2006-05-26
AP2005003325A0 (en)	2005-06-30
OA13014A (en)	2006-11-10
IS7843A (is)	2005-05-12
DK1572214T3 (da)	2010-06-07
NZ540505A (en)	2007-02-23
TW200423944A (en)	2004-11-16
JP3889775B2 (ja)	2007-03-07
JP2007084575A (ja)	2007-04-05
CY1110130T1 (el)	2015-01-14
CR7869A (es)	2005-07-08
PL377480A1 (pl)	2006-02-06
EA009589B1 (ru)	2008-02-28
NL1024983C2 (nl)	2005-02-01
PE20040906A1 (es)	2005-01-24
KR20050094813A (ko)	2005-09-28
NL1024983A1 (nl)	2004-06-11
MXPA05006151A (es)	2005-08-26
GEP20074272B (en)	2007-12-25
AR042339A1 (es)	2005-06-15
JP3920908B2 (ja)	2007-05-30
MY144338A (en)	2011-08-29
UY28117A1 (es)	2004-07-30
NO330143B1 (no)	2011-02-21
JP4624341B2 (ja)	2011-02-02
PT1572214E (pt)	2010-05-06
HN2003000401A (es)	2004-11-23
RS20050445A (en)	2007-04-10
WO2004052372A1 (en)	2004-06-24
NO20052557D0 (no)	2005-05-26
ECSP055850A (es)	2005-09-20
SI1572214T1 (sl)	2010-07-30
RS51442B (en)	2011-04-30
MA27605A1 (fr)	2005-11-01
ATE460938T1 (de)	2010-04-15
CA2508262C (en)	2009-12-01
CO5700781A2 (es)	2006-11-30
KR100796102B1 (ko)	2008-01-21
JP2006232857A (ja)	2006-09-07
AU2003302878B2 (en)	2009-04-23
AU2003302878A1 (en)	2004-06-30
PA8591601A1 (es)	2004-12-16
NO20052557L (no)	2005-09-06
EA200500801A1 (ru)	2005-12-29
CA2508262A1 (en)	2004-06-24
HRP20050523A2 (en)	2005-08-31
ES2339767T3 (es)	2010-05-25
EP1572214B1 (de)	2010-03-17

Legal Events

Date	Code	Title	Description
2011-04-07	8364	No opposition during term of opposition

Publication	Publication Date	Title
CY2012028I1 (el)	2017-04-05	Η χρηση δαποξετινης, ενος ταχειας-εναρξης επιλεκτικου αναστολεα εκ νεου αναληψης σepοτονινης για την θepαπευτικη αντιμετωπιση σεξουαλικης δυσλειτουργιας
IS2494B (is)	2009-02-15	Notkun á morfólínóli til meðhöndlunar á kynferðislegri vanvirkni
AP2223A (en)	2011-03-24	Pramipexole once-daily dosage form.
PL377729A1 (pl)	2006-02-06	Sposób leczenia dysfunkcji seksualnej
IS7738A (is)	2005-03-10	Þíasól efnasambönd til notkunar í meðferð á taugahrörnunar truflunum.
DE50214540D1 (de)	2010-08-26	Stanz bei der behandlung von wunden
NO20040936L (no)	2004-06-04	Plaster for behandling av dysfunksjoner og forstyrrelser ved neglevekst.
DE60331769D1 (de)	2010-04-29	Sten in der behandlung von u.a. sexueller dysfunktion
AU2003219981A1 (en)	2003-09-22	Benzimidazole-derivatives for the treatment of sexual dysfunction
DE60329308D1 (de)	2009-10-29	Oberflächenbehandlung
NO20030978D0 (no)	2003-02-28	Behandling av diuresedysfunksjon
ATE369136T1 (de)	2007-08-15	Therapeutische behandlung
EG24959A (en)	2011-02-18	Indoles useful in the treatment of androgenreceptor related diseases.
DE50009813D1 (de)	2005-04-21	Kombinationpräparat zur behandlung von sexueller dysfunktion
ITRM20010708A0 (it)	2001-12-04	Uso di una alcanoil l-carnitina per il trattamento della disfunzione erettile.
ATE345818T1 (de)	2006-12-15	S-methyl-dihydro-ziprasidone zur behandlung von psychiatrischen störungen.
ATE390144T1 (de)	2008-04-15	Behandlung von fibrosen
GB0225815D0 (en)	2002-12-11	Soil Treatment
NO20022747L (no)	2003-12-08	Behandlingsstol
ITMI20001867A0 (it)	2000-08-10	Metodo di trattamento di reflui.
GB0217464D0 (en)	2002-09-04	Soil treatment
ES1051647Y (es)	2003-04-16	Depuradora de aguas residuales.
IT1317752B1 (it)	2003-07-15	Procedimento per il trattamento di fanghi.
ITVR20030025A1 (it)	2004-09-07	Ortesi polso-dito.
ZA200308797B (en)	2004-06-01	Water treatment composition.